Astrazeneca Pharma India Ltd

- No explicit mention of any current or future fundraising plans through debt or equity in the provided pages. - The Company is described as a "zero debt Company" as of 2024-2025 (Page 21). - The leadership affirms ongoing evaluation of investments, CAPEX, and resource allocation, but no specific fundraising activity is detailed (Page 22). - Shareholders inquire about CAPEX plans and cash utilization; management assures prudent investments but does not indicate raising capital via debt or equity (Page 22). - Dividend increases and discussions around cost management imply internal funding is currently sufficient (Page 21). - There are no comments on issuing bonus shares or rights issues beyond shareholder suggestions, but no commitments from management (Page 21, 19). In summary, AstraZeneca Pharma India Limited currently holds zero debt and has not disclosed any plans for fundraising via debt or equity.

- The Company continues to evaluate investments needed in India periodically. - As a global company committed to India, AstraZeneca plans to make the right level of CAPEX investments over the next several years aligned with its plans for India. - There is a focus on supporting growth through activities like marketing, medical personnel, and logistics, which impact costs. - Investment in clinical trials, especially Phase IV trials for new product launches, is ongoing. - No specific CAPEX figures or projects were detailed, but the assurance is given that strategic and appropriate investments will be made as required.

- AstraZeneca Pharma India expects robust future growth driven primarily by oncology and biopharmaceutical portfolios. - Company plans multiple new product launches over the coming years, including rare disease products like Soliris. - The rare disease segment is an emerging focus area, aiming to build awareness and diagnosis capabilities in India, with potential to represent 15-16% of sales globally. - Growth in oncology has been phenomenal, with cancer portfolio currently constituting around 70%-75% of sales; diversification efforts are ongoing to balance this. - Revenue growth recorded was 32% in FY 2024-25; management is confident in sustaining high growth, with aspirations to double turnover every two years leading up to 2030. - AstraZeneca India aims to become a billion-dollar company by 2030, contributing about 1% of the global portfolio. - R&D investments and strategic marketing efforts will continue to support scaling and innovation. - The overall vision projects "sky is the limit" as long as patient-centric innovation and cause commitment continues.

- The Company reported a 32% revenue growth in FY 2024-25 and a 25% growth in profit before exceptional items and tax, signaling strong momentum. - Earnings per share (EPS) before exceptional items increased by 25%, despite a reduction after exceptional items due to strategic one-off costs. - Management is confident in continued growth driven by innovative product launches, particularly in Oncology and Biopharmaceuticals. - The rare diseases portfolio, though early-stage, is expected to grow steadily, contributing meaningfully over the next decade. - Investments in marketing, clinical trials, and logistics may increase operating costs in the short term but are aimed at sustaining long-term growth. - CAPEX and R&D investments will be aligned with growth plans, ensuring the introduction of new products benefiting patients in India. - The vision is robust growth without specifying exact figures, with a focus on expanding the product portfolio and market leadership. - Inventory build-up aligns with expected future demand, supporting sales growth and operational readiness.

The provided pages of the AstraZeneca Pharma India Limited document do not contain specific information regarding the current or expected order book or pending orders. The discussion primarily revolves around: - Financial performance and growth outlook. - Questions from shareholders related to products, CAPEX plans, R&D expenditure. - Inventory levels and their relation to growth plans. - Strategic focus on Oncology, Biopharmaceuticals, and Rare Diseases. - Shareholders' queries on dividends, share price, and company vision. No explicit details or figures related to order book or pending orders are mentioned in the content from pages 15 to 23.